Doctor with Vaccine

AM-Pharma Enrolls First Patients in Covid-19 Phase III Trial

AM-Pharma has recruited first patients with Covid-19 infection and sepsis-associated acute kidney injury (SA-AKI) in an exploratory cohort of its phase III REVIVAL pivotal trial.

The phase III randomised, double-blind, placebo-controlled, two-arm, parallel-group and multi-centre study will assess safety, tolerability and clinical benefit of the company’s human recombinant alkaline phosphatase to treat patients with SA-AKI.

AM-Pharma will recruit up to 1,400 patients with SA-AKI in the main study population. The company will recruit up to 100 patients with moderate chronic kidney disease (CKD) and up to 100 patients with Covid-19 in two exploratory cohorts.

Read more…